Published in West J Med on March 01, 1987
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973) 7.47
SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci (1982) 3.82
Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A (1984) 3.13
Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science (1982) 3.10
A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med (1957) 2.75
Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature (1982) 2.44
III. Partial Hypophysectomy for Acromegaly: With Remarks on the Function of the Hypophysis. Ann Surg (1909) 2.26
Long-term treatment of acromegaly with bromocriptine. Br Med J (1977) 2.18
FAMILIAL MULTIPLE ENDOCRINE ADENOMA-PEPTIC ULCER COMPLEX. Medicine (Baltimore) (1964) 1.82
Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology (1983) 1.72
Colonic polyps in patients with acromegaly. Ann Intern Med (1982) 1.71
Prolactin and growth hormone in patients with pituitary adenomas: a correlative study of hormone in tumor and plasma by immunoperoxidase technique and radioimmunoassay. J Clin Endocrinol Metab (1974) 1.60
Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest (1982) 1.60
Binding of nonsuppressible insulinlike activity to human serum. Evidence for a carrier protein. Arch Biochem Biophys (1975) 1.52
The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med (1982) 1.49
Ultrastructural classification of pituitary adenomas. Can J Neurol Sci (1976) 1.43
Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med (1985) 1.41
Pathophysiology of acromegaly. Endocr Rev (1983) 1.35
Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science (1981) 1.33
Partial purification and characterization of a peptide with growth hormone-releasing activity from extrapituitary tumors in patients with acromegaly. J Clin Invest (1980) 1.31
Ultrastructure of human sella tumors. Correlations of clinical findings and morphology. Acta Neurochir (Wien) (1975) 1.26
Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man. Lancet (1983) 1.23
Demonstration of specific plasma protein binding sites for somatomedin. J Clin Endocrinol Metab (1977) 1.19
Arginine-initiated release of human growth hormone. Factors modifying the response in normal man. N Engl J Med (1969) 1.17
Regulation of growth hormone secretion in acromegaly. J Clin Endocrinol Metab (1969) 1.15
Conventional radiation therapy in acromegaly. A review and reassessment. Arch Intern Med (1971) 1.14
The chemistry of growth hormone and the lactogenic hormones. Recent Prog Horm Res (1973) 1.13
Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med (1979) 1.13
NMR Study of ganglion-blocking and curare-like dimethoniums conformation in aqueous solutions. FEBS Lett (1972) 1.10
Intrasellar neural-adenohypophyseal choristoma. A morphological and immunocytochemical study. J Neuropathol Exp Neurol (1982) 1.09
Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment. Acta Endocrinol (Copenh) (1978) 1.08
Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet (1979) 1.08
Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab (1979) 1.07
Acromegaly associated with a bronchial carcinoid tumor: evidence for ectopic production of growth hormone-releasing activity. J Clin Endocrinol Metab (1979) 1.07
Acromegaly and Cushing's syndrome associated with a foregut carcinoid tumor. J Clin Endocrinol Metab (1981) 1.07
Transsphenoidal microsurgery in the treatment of acromegaly and gigantism. J Clin Endocrinol Metab (1980) 1.05
Growth hormone dynamics in acromegaly. J Clin Endocrinol Metab (1970) 1.03
Treatment of acromegaly by trans-sphenoidal operation, 90-yttrium implantation and bromocriptine: results in 230 patients. Clin Endocrinol (Oxf) (1982) 1.02
Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients. J Clin Endocrinol Metab (1975) 1.01
The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab (1985) 0.99
Pituitary adenomas: clinicopathological and immunohistochemical study. Ann Neurol (1980) 0.99
Bronchial carcinoid tumour with acromegaly in two patients. J Clin Endocrinol Metab (1974) 0.99
Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab (1984) 0.99
Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery? JAMA (1982) 0.98
Chromophobe pituitary adenoma with acromegaly and TSH-induced hyperthyroidism associated with parathyroid adenoma. Acromegaly and parathyroid adenoma. Acta Endocrinol (Copenh) (1969) 0.97
Human mixed somatotrophic and lactotrophic pituitary adenomas. J Clin Endocrinol Metab (1976) 0.97
Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med (1985) 0.97
Histologic, ultrastructural and hormonal characterization of a pituitary tumor secreting both HGH and prolactin. J Clin Endocrinol Metab (1973) 0.96
Acromegaly due to production of a growth hormone releasing factor by a bronchial carcinoid tumor. Clin Endocrinol (Oxf) (1979) 0.96
Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: plasma GRF levels in 177 acromegalic patients. J Clin Endocrinol Metab (1984) 0.96
Acromegaly caused by pulmonary carcinoid tumours. Clin Endocrinol (Oxf) (1976) 0.95
Acromegaly and colon cancer. Ann Intern Med (1984) 0.95
Conventional pituitary irradiation in acromegaly. Effect on growth hormone and TSH secretion. Acta Endocrinol (Copenh) (1976) 0.94
Studies on the role of RNA and protein synthesis in the lipolytic action of growth hormone in isolated fat cells. Adv Enzyme Regul (1967) 0.94
The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest (1982) 0.94
A unique growth factor in patients with acromegaloidism. J Clin Endocrinol Metab (1983) 0.92
Pituitary tumors secreting growth hormone and prolactin. Ann Intern Med (1986) 0.91
Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer (1981) 0.90
Ultrastructure, immunohistochemistry and hormone release of pituitary adenomas in relation to prolactin production. Virchows Arch A Pathol Anat Histol (1980) 0.90
Cure of acromegaly by operative removal of an islet cell tumor of the pancreas. Am J Med (1978) 0.89
Recovery from paradoxical growth hormone responses in acromegaly after transphenoidal selective adenomectomy. J Clin Endocrinol Metab (1975) 0.88
Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. J Clin Endocrinol Metab (1972) 0.87
Acromegaly: analysis of 132 cases treated surgically. Neurosurgery (1981) 0.87
Mechanism of estrogenic action in acromegaly. J Clin Invest (1969) 0.86
Suppression of growth hormone-dependent human serum sulfation factor by estrogen. J Clin Endocrinol Metab (1972) 0.86
Ectopic pituitary adenomas. Clin Endocrinol (Oxf) (1979) 0.85
Morphological and biochemical relationships in 31 human pituitary adenomas with acromegaly. Virchows Arch A Pathol Anat Histol (1980) 0.85
Pituitary adenomas with hyperfunction of TSH. Frequency, histological classification, immunocytochemistry and ultrastructure. Virchows Arch A Pathol Anat Histol (1982) 0.84
Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells. J Clin Endocrinol Metab (1986) 0.84
Ectopic growth hormone syndrome associated with lung cancer. Metabolism (1971) 0.84
Growth hormone: metabolic clearance rates, integrated concentrations, and production rates in normal adults and the effect of prednisone. J Clin Invest (1972) 0.84
The cytology of a human pituitary tumor: an electron microscopic study. Trans Am Microsc Soc (1966) 0.83
Nutrition and somatomedin. XIII. Usefulness of somatomedin-C in nutritional assessment. Am J Med (1985) 0.83
Chromophobe and acidophil adenomas of the human pituitary gland. A light and electron microscopic study. Acta Pathol Microbiol Scand Suppl (1962) 0.83
Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. A review of 137 cases. J Neurosurg (1982) 0.82
Hyperprolactinemia. Morphologic and clinical considerations. Med Clin North Am (1978) 0.82
Reticulum stain for frozen-section diagnosis of pituitary adenomas. Technical note. J Neurosurg (1977) 0.81
Plasma prolactin in acromegaly before and after treatment. J Clin Endocrinol Metab (1981) 0.81
Use of immunohistochemical and morphologic methods for the identification of human growth hormone-producing pituitary adenomas. Cancer (1976) 0.81
Blunted growth hormone (GH) response to GH-releasing hormone in hypothyroidism resolves in the euthyroid state. J Clin Endocrinol Metab (1985) 0.80
Thyroid function in acromegaly. Lancet (1971) 0.80
Calcium and vitamin D metabolism in acromegaly. Acta Endocrinol (Copenh) (1981) 0.79
Circadian regulation of growth hormone secretion after treatment in acromegaly. J Clin Endocrinol Metab (1980) 0.79
Acromegaly with an adenomatous pharyngeal pituitary. JAMA (1980) 0.79
Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response. J Clin Endocrinol Metab (1981) 0.79
Immunostaining of growth hormone and prolactin in paraffin-embedded and stored or previously stained materials. J Histochem Cytochem (1978) 0.79
Bromocriptine therapy in acromegaly. A long-term review of 35 cases. Postgrad Med J (1981) 0.78
The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab (1982) 0.78
Acromegaly: reassessment of the long-term therapeutic effectiveness of transsphenoidal pituitary surgery. Ann Intern Med (1981) 0.78
Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clin Endocrinol (Oxf) (1982) 0.78
Transsphenoidal microhypophysectomy in acromegaly. J Neurosurg (1977) 0.78
Electron microscopic studies of human pituitary tumors. II. Acidophilic adenomas. Am J Anat (1973) 0.77
Heel pad thickness in acromegaly. Br J Radiol (1970) 0.77
A new treatment for an old disease. N Engl J Med (1985) 0.76
Histochemical reactivity and staining properties of functionally defined cell types in the human adenohypophysis. Am J Pathol (1973) 0.76
Bromocriptine treatment of acromegaly. Metabolism (1977) 0.76
Changes in bone metabolism during treatment of acromegaly. Acta Endocrinol (Copenh) (1983) 0.76
The effect of growth hormone on splanchnic glucose and substrate metabolism following oral glucose loading in healthy man. Diabetes (1984) 0.76
Progestins in the medical management of active acromegaly. J Clin Endocrinol Metab (1970) 0.76
Effect of bromocriptine on serum hormones in acromegaly. Horm Res (1984) 0.76
Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science (2000) 4.17
Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res (1997) 3.06
Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1997) 2.90
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet (2000) 2.39
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab (2000) 2.27
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab (2010) 2.16
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci U S A (1999) 2.04
Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology (2000) 1.93
Clonal origin of pituitary adenomas. J Clin Endocrinol Metab (1990) 1.81
Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1999) 1.78
Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab (1998) 1.74
Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med (1999) 1.72
Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab (1999) 1.69
Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.68
Colon polyps in acromegaly. Ann Intern Med (1991) 1.66
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab (2008) 1.66
Targeted overexpression of parathyroid hormone-related protein (PTHrP) to vascular smooth muscle in transgenic mice lowers blood pressure and alters vascular contractility. Endocrinology (1999) 1.64
Cell-specific signal transduction of parathyroid hormone (PTH)-related protein through stably expressed recombinant PTH/PTHrP receptors in vascular smooth muscle cells. Endocrinology (1996) 1.61
Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol (2001) 1.61
Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab (1996) 1.53
Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol (1990) 1.50
Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab (1998) 1.48
Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene (2011) 1.48
Frequent loss of heterozygosity at chromosome 3p14.2-3p21 in human pancreatic islet cell tumours. Clin Endocrinol (Oxf) (1999) 1.45
Clinical, quality of life, and economic value of acromegaly disease control. Pituitary (2011) 1.44
Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab (2000) 1.41
Human fetal pituitary expresses functional growth hormone-releasing peptide receptors. J Clin Endocrinol Metab (1998) 1.38
Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. J Clin Invest (1997) 1.37
Pathophysiology of acromegaly. Endocr Rev (1983) 1.35
Letter: Metoclopramide and facial dyskinesia. Br Med J (1975) 1.33
Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology (1998) 1.33
Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res (1990) 1.32
Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev (2000) 1.28
Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem (2000) 1.24
The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene (2000) 1.23
Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. J Clin Invest (2000) 1.23
Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab (1981) 1.22
Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab (1995) 1.21
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab (2013) 1.21
Leukemia inhibitory factor modulates interleukin-1beta-induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology (1998) 1.19
Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. Circ Res (1996) 1.19
Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A (1994) 1.18
Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab (1999) 1.18
Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest (1999) 1.17
Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab (2001) 1.17
Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest (1996) 1.14
Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol Endocrinol (1998) 1.11
Relative increase in insulin-like growth factor I messenger ribonucleic acid levels in compensatory renal hypertrophy. Endocrinology (1987) 1.11
Pituitary cytokine and growth factor expression and action. Endocr Rev (1997) 1.10
Current management practices for acromegaly: an international survey. Pituitary (2011) 1.10
Somatotroph insulin-like growth factor-I signaling. Ann N Y Acad Sci (1993) 1.09
Clinical review 18: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab (1991) 1.07
Management of pituitary tumors. Ann Intern Med (1998) 1.07
Ets-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells. Am J Physiol (1998) 1.07
Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. J Clin Invest (1995) 1.07
Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene (2007) 1.06
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest (1997) 1.06
Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation (1982) 1.05
Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol (2000) 1.05
Solitary polyclonal autonomous thyroid nodule: a rare cause of childhood hyperthyroidism. J Clin Endocrinol Metab (1991) 1.05
Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab (1998) 1.05
RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer (2005) 1.04
Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene (1999) 1.02
Regulation of insulin-like growth factor-I and its receptor in rat aorta after balloon denudation. Evidence for local bioactivity. J Clin Invest (1992) 1.01
Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. Endocrinology (1996) 1.01
Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab (1995) 1.00
Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res (1995) 1.00
Critical role for STAT3 in murine pituitary adrenocorticotropin hormone leukemia inhibitory factor signaling. J Biol Chem (1999) 1.00
Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. Endocrinology (2001) 1.00
Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab (1994) 1.00
The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J Clin Invest (2001) 1.00
Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. Clin Cancer Res (1996) 0.99
Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. J Clin Invest (1987) 0.99
Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab (1994) 0.99
The MKK6/p38 mitogen-activated protein kinase pathway is capable of inducing SOCS3 gene expression and inhibits IL-6-induced transcription. Biol Chem (2001) 0.98
From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization. Am J Hum Genet (1998) 0.98
Oncogene activation in pituitary tumors. Brain Pathol (2001) 0.97
Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene (1996) 0.97
Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med (1985) 0.97
Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab (2012) 0.97
Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology (1986) 0.96
H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab (1990) 0.96
Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest (1997) 0.96
Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab (1993) 0.95
Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology (1992) 0.95
Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle alpha-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia. Endocrinology (1998) 0.95
Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. Endocrinology (1999) 0.94
Angiotensin II regulates parathyroid hormone-related protein expression in cultured rat aortic smooth muscle cells through transcriptional and post-transcriptional mechanisms. J Biol Chem (1993) 0.94
The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. J Clin Endocrinol Metab (1993) 0.94
Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J Endocrinol (1998) 0.93
Cloning and characterization of alternatively spliced isoforms of rat tenascin. Platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. J Biol Chem (1994) 0.92
Pituitary tumor transforming gene 1 regulates Aurora kinase A activity. Oncogene (2008) 0.92
A common pro-opiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy. J Biol Chem (1997) 0.92
Insulin regulation of rat growth hormone gene transcription. J Clin Invest (1986) 0.92
Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab (2011) 0.92